Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04165850 | Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS | PHASE2 | COMPLETED | 16 | — | — | Nov 25, 2019 | Jan 19, 2021 | Mar 3, 2021 | 1 | Israel |
Treatment emergent adverse event is any medical event associated with the drug
Number of patients whose treatment is stopped prematurely for any reason
Number of patients whose treatment is stopped prematurely specifically due to adverse events
| Arm | Type | Description |
|---|---|---|
| Fixed dose Ciprofloxacin and Celecoxib | EXPERIMENTAL | Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day |
| Name | Type | Description |
|---|---|---|
| Fixed dose combination Ciprofloxacin/Celecoxib | DRUG | Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day |
Inclusion Criteria: 1. Able to comprehend and willing to sign an Informed Consent Form (ICF) 2. Males or females between the ages of 18 and 75 years of age, inclusive 3. Diagnosis of familial or sporadic ALS (defined as meeting the laboratory-supported probable, probable, or definite criteria for a...